Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(2):381–384. doi: 10.1054/bjoc.1999.0930

Screen-detected breast cancers have a lower mitotic activity index

R P R Groenendijk 1, P Bult 2, L Tewarie 1, P G M Peer 3, R F van der Sluis 1, T J M Ruers 1, T Wobbes 1
PMCID: PMC2363302  PMID: 10646892

Abstract

We know that screening for breast cancer leads to detection of smaller tumours with less lymph node metastases. Could it be possible that the decrease in mortality after screening is not only caused by this earlier stage, but also by a different mitotic activity index (MAI) of the tumours that are detected by screening? Is MAI a prognostic factor for recurrence-free survival? A retrospective study was carried out of 387 patients with breast cancer, treated at the University Hospital Nijmegen between January 1992 and September 1997. Ninety patients had screen-detected breast cancer, 297 patients had breast cancers detected outside the screening programme. The MAI, other prognostic factors and recurrence-free survival were determined. In non-screen-detected tumours the MAI is twice as high as in screen-detected tumours, even after correction for age took place. The MAI correlated well with other tumour characteristics. The MAI in itself is a prognostic factor for recurrence-free survival. Favourable outcome in screen detected breast cancer is not entirely caused by detecting cancer in early stages: quantitative features such as the MAI indicate a less malignant character of screen detected breast cancer. The MAI is an independent prognostic factor for recurrence-free survival. © 2000 Cancer Research Campaign

Keywords: breast, cancer, screening mitotic, activity, index

Full Text

The Full Text of this article is available as a PDF (59.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaltomaa S., Lipponen P., Eskelinen M., Alhava E., Syrjänen K. Nuclear morphometry and mitotic indexes as prognostic factors in breast cancer. Eur J Surg. 1991 May;157(5):319–324. [PubMed] [Google Scholar]
  2. Aaltomaa S., Lipponen P., Eskelinen M., Kosma V. M., Marin S., Alhava E., Syrjänen K. Predictive value of a morphometric prognostic index in female breast cancer. Oncology. 1993;50(1):57–62. doi: 10.1159/000227148. [DOI] [PubMed] [Google Scholar]
  3. Baak J. P. The relative prognostic significance of nucleolar morphometry in invasive ductal breast cancer. Histopathology. 1985 Apr;9(4):437–444. doi: 10.1111/j.1365-2559.1985.tb02826.x. [DOI] [PubMed] [Google Scholar]
  4. Baak J. P., Van Dop H., Kurver P. H., Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer. 1985 Jul 15;56(2):374–382. doi: 10.1002/1097-0142(19850715)56:2<374::aid-cncr2820560229>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  5. Baak J. P., Wisse-Brekelmans E. C., Kurver P. H., van Gorp L. H., Voorhorst F. J., Miettinen O. S. Regional differences in breast cancer survival are correlated with differences in differentiation and rate of proliferation. Hum Pathol. 1992 Sep;23(9):989–992. doi: 10.1016/0046-8177(92)90259-6. [DOI] [PubMed] [Google Scholar]
  6. Baak J. P., van Diest P. J., Ariens A. T., van Beek M. W., Bellot S. M., Fijnheer J., van Gorp L. H., Kwee W. S., Los J., Peterse H. C. The Multicenter Morphometric Mammary Carcinoma Project (MMMCP). A nationwide prospective study on reproducibility and prognostic power of routine quantitative assessments in The Netherlands. Pathol Res Pract. 1989 Nov;185(5):664–670. doi: 10.1016/S0344-0338(89)80213-4. [DOI] [PubMed] [Google Scholar]
  7. Baak J. P., van Diest P. J., Benraadt T., Matze-Cok E., Brugghe J., Schuurmans L. T., Littooy J. J. The Multi-Center Morphometric Mammary Carcinoma Project (MMMCP) in The Netherlands: value of morphometrically assessed proliferation and differentiation. J Cell Biochem Suppl. 1993;17G:220–225. doi: 10.1002/jcb.240531141. [DOI] [PubMed] [Google Scholar]
  8. Borràs J. M., Espinas J. A., Beemsterboer P. M., Granados A., de Koning H. J. Anticipating the consequences for the primary therapy of breast cancer after introducing screening. A more global picture for health care policy making. Int J Technol Assess Health Care. 1998 Spring;14(2):268–276. doi: 10.1017/s0266462300012241. [DOI] [PubMed] [Google Scholar]
  9. Collan Y. U., Kuopio T., Baak J. P., Becker R., Bogomoletz W. V., Deverell M., van Diest P., van Galen C., Gilchrist K., Javed A. Standardized mitotic counts in breast cancer. Evaluation of the method. Pathol Res Pract. 1996 Sep;192(9):931–941. doi: 10.1016/S0344-0338(96)80075-6. [DOI] [PubMed] [Google Scholar]
  10. Fracheboud J., de Koning H. J., Beemsterboer P. M., Boer R., Hendriks J. H., Verbeek A. L., van Ineveld B. M., de Bruyn A. E., van der Maas P. J. Nation-wide breast cancer screening in The Netherlands: results of initial and subsequent screening 1990-1995. National Evaluation Team for Breast Cancer Screening. Int J Cancer. 1998 Mar 2;75(5):694–698. doi: 10.1002/(sici)1097-0215(19980302)75:5<694::aid-ijc6>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  11. Freund K. M., Burns R. B., Antab L. Improving residents' performances of clinical breast examination. J Cancer Educ. 1998 Spring;13(1):20–25. doi: 10.1080/08858199809528506. [DOI] [PubMed] [Google Scholar]
  12. Harris K. M., Vogel V. G. Breast cancer screening. Cancer Metastasis Rev. 1997 Sep-Dec;16(3-4):231–262. doi: 10.1023/a:1005893126451. [DOI] [PubMed] [Google Scholar]
  13. Jannink I., van Diest P. J., Baak J. P. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol. 1995 Oct;26(10):1086–1092. doi: 10.1016/0046-8177(95)90270-8. [DOI] [PubMed] [Google Scholar]
  14. Maestro C., Cazenave F., Marcy P. Y., Bruneton J. N., Chauvel C., Bleuse A. Systematic ultrasonography in asymptomatic dense breasts. Eur J Radiol. 1998 Feb;26(3):254–256. doi: 10.1016/s0720-048x(97)01166-2. [DOI] [PubMed] [Google Scholar]
  15. Miltenburg G. A., Peeters P. H., Fracheboud J., Collette H. J. Seventeen-year evaluation of breast cancer screening: the DOM project, The Netherlands. Diagnostisch Onderzoek (investigation) Mammacarcinoom. Br J Cancer. 1998 Oct;78(7):962–965. doi: 10.1038/bjc.1998.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Peer P. G., Verbeek A. L., Straatman H., Hendriks J. H., Holland R. Age-specific sensitivities of mammographic screening for breast cancer. Breast Cancer Res Treat. 1996;38(2):153–160. doi: 10.1007/BF01806669. [DOI] [PubMed] [Google Scholar]
  17. Schroën A. A., Wobbes T., van der Sluis R. F. Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol. 1996 Nov;63(3):141–144. doi: 10.1002/(SICI)1096-9098(199611)63:3<141::AID-JSO2>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  18. Schroën A. M., Wobbes T., van der Sluis R. F. Infiltrating lobular carcinoma of the breast detected by screening. Br J Surg. 1998 Mar;85(3):390–392. doi: 10.1046/j.1365-2168.1998.00608.x. [DOI] [PubMed] [Google Scholar]
  19. Smart C. R. Mammographic screening: efficacy and guidelines. Curr Opin Radiol. 1992 Oct;4(5):108–117. [PubMed] [Google Scholar]
  20. Tabár L., Fagerberg C. J., Gad A., Baldetorp L., Holmberg L. H., Gröntoft O., Ljungquist U., Lundström B., Månson J. C., Eklund G. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985 Apr 13;1(8433):829–832. doi: 10.1016/s0140-6736(85)92204-4. [DOI] [PubMed] [Google Scholar]
  21. Theissig F., Baak J. P., Schuurmans L., Haroske G., Meyer W., Kunze K. D. 'Blind' multicenter evaluation of the prognostic value of DNA image cytometric and morphometric features in invasive breast cancer. Anal Cell Pathol. 1996 Mar;10(2):85–99. [PubMed] [Google Scholar]
  22. Uyterlinde A. M., Baak J. P., Schipper N. W., Peterse H., Matze E., Meijer C. J. Further evaluation of the prognostic value of morphometric and flow cytometric parameters in breast-cancer patients with long follow-up. Int J Cancer. 1990 Jan 15;45(1):1–7. doi: 10.1002/ijc.2910450102. [DOI] [PubMed] [Google Scholar]
  23. Uyterlinde A. M., Schipper N. W., Baak J. P. Comparison of extent of disease and morphometric and DNA flow cytometric prognostic factors in invasive ductal breast cancer. J Clin Pathol. 1987 Dec;40(12):1432–1436. doi: 10.1136/jcp.40.12.1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Uyterlinde A. M., Schipper N. W., Baak J. P., Peterse H., Matze E. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer. Am J Clin Pathol. 1988 Mar;89(3):301–307. doi: 10.1093/ajcp/89.3.301. [DOI] [PubMed] [Google Scholar]
  25. Van Dijck J. A., Verbeek A. L., Beex L. V., Hendriks J. H., Holland R., Mravunac M., Straatman H., Werre J. M. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65. Int J Cancer. 1997 Jan 17;70(2):164–168. doi: 10.1002/(sici)1097-0215(19970117)70:2<164::aid-ijc5>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  26. Verbeek A. L., Hendriks J. H., Holland R., Mravunac M., Sturmans F., Day N. E. Reduction of breast cancer mortality through mass screening with modern mammography. First results of the Nijmegen project, 1975-1981. Lancet. 1984 Jun 2;1(8388):1222–1224. doi: 10.1016/s0140-6736(84)91703-3. [DOI] [PubMed] [Google Scholar]
  27. van Diest P. J., Baak J. P., Matze-Cok P., Bacus S. S. Prediction of response to adjuvant chemotherapy in premenopausal lymph node positive breast cancer patients with morphometry, DNA flow cytometry and HER-2/neu oncoprotein expression. Preliminary results. Pathol Res Pract. 1992 Apr;188(3):344–349. doi: 10.1016/S0344-0338(11)81215-X. [DOI] [PubMed] [Google Scholar]
  28. van Diest P. J., Fleege J. C., Baak J. P. Syntactic structure analysis in invasive breast cancer: analysis of reproducibility, biologic background, and prognostic value. Hum Pathol. 1992 Aug;23(8):876–883. doi: 10.1016/0046-8177(92)90398-m. [DOI] [PubMed] [Google Scholar]
  29. van Dijck J. A., Broeders M. J., Verbeek A. L. Mammographic screening in older women. Is it worthwhile? Drugs Aging. 1997 Feb;10(2):69–79. doi: 10.2165/00002512-199710020-00001. [DOI] [PubMed] [Google Scholar]
  30. van der Linden H. C., Baak J. P., Lindeman J., Hermans J., Meyer C. J. Morphometry and breast cancer. II. Characterisation of breast cancer cells with high malignant potential in patients with spread to lymph nodes: preliminary results. J Clin Pathol. 1986 Jun;39(6):603–609. doi: 10.1136/jcp.39.6.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. van der Linden J. C., Baak J. P., Lindeman J., Hermans J., Meyer C. J. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol. 1987 Mar;40(3):302–306. doi: 10.1136/jcp.40.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. van der Linden J. C., Lindeman J., Baak J. P., Meijer C. J., Herman C. J. The Multivariate Prognostic Index and nuclear DNA content are independent prognostic factors in primary breast cancer patients. Cytometry. 1989 Jan;10(1):56–61. doi: 10.1002/cyto.990100110. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES